このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Apellis Pharmaceuticals 将来の成長

Future 基準チェック /66

Apellis Pharmaceuticals利益と収益がそれぞれ年間62.7%と25.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に37.8% 61.8%なると予測されています。

主要情報

62.7%

収益成長率

61.8%

EPS成長率

Biotechs 収益成長	30.2%
収益成長率	25.6%
将来の株主資本利益率	37.8%
アナリストカバレッジ	Good
最終更新日	18 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:1JK - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,668	393	425	305	14
12/31/2025	1,198	105	211	178	15
12/31/2024	821	-129	-165	-122	17
3/31/2024	524	-417	-551	-550	N/A
12/31/2023	397	-529	-596	-595	N/A
9/30/2023	273	-606	-639	-638	N/A
6/30/2023	185	-657	-625	-623	N/A
3/31/2023	106	-691	-582	-580	N/A
12/31/2022	75	-652	-515	-514	N/A
9/30/2022	113	-634	-486	-485	N/A
6/30/2022	97	-638	-501	-500	N/A
3/31/2022	81	-702	-522	-521	N/A
12/31/2021	67	-746	-564	-563	N/A
9/30/2021	256	-520	-310	-309	N/A
6/30/2021	251	-460	-245	-240	N/A
3/31/2021	251	-360	-211	-205	N/A
12/31/2020	251	-345	-166	-160	N/A
9/30/2020	1	-536	-389	-385	N/A
6/30/2020	N/A	-470	-340	-338	N/A
3/31/2020	N/A	-423	-285	-284	N/A
12/31/2019	N/A	-305	-213	-211	N/A
9/30/2019	N/A	-228	-175	-174	N/A
6/30/2019	N/A	-194	-154	-153	N/A
3/31/2019	N/A	-156	-145	-144	N/A
12/31/2018	N/A	-128	-131	-131	N/A
9/30/2018	N/A	-109	-102	-102	N/A
6/30/2018	N/A	-85	-80	-80	N/A
3/31/2018	N/A	-64	-61	-61	N/A
12/31/2017	N/A	-51	N/A	-47	N/A
9/30/2017	N/A	-39	N/A	-38	N/A
6/30/2017	N/A	-35	N/A	-33	N/A
3/31/2017	N/A	-30	N/A	-28	N/A
12/31/2016	N/A	-27	N/A	-26	N/A
9/30/2016	N/A	-29	N/A	-27	N/A
6/30/2016	N/A	-53	N/A	-24	N/A
3/31/2016	N/A	-50	N/A	-21	N/A
12/31/2015	N/A	-47	N/A	-19	N/A
9/30/2015	N/A	-41	N/A	-14	N/A
6/30/2015	N/A	-12	N/A	-14	N/A
3/31/2015	N/A	-12	N/A	-12	N/A
12/31/2014	N/A	-11	N/A	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1JKは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.7% ) よりも高い成長率であると考えられます。

収益対市場: 1JK今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 1JK今後 3 年以内に収益を上げることが予想されます。

収益対市場: 1JKの収益 ( 25.6% ) German市場 ( 5.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: 1JKの収益 ( 25.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1JKの自己資本利益率は、3年後には高くなると予測されています ( 37.8 %)

Apellis Pharmaceuticals 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Forecast to breakeven in 2025

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

First quarter 2024 earnings released: US$0.54 loss per share (vs US$1.56 loss in 1Q 2023)

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Full year 2023 earnings released: US$4.45 loss per share (vs US$6.15 loss in FY 2022)

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings released: US$1.02 loss per share (vs US$1.46 loss in 2Q 2022)

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Insufficient new directors

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Forecast to breakeven in 2025

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

Insufficient new directors

Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS Annual Scientific Meeting

Insider recently sold €116k worth of stock

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

No longer forecast to breakeven

Apellis Pharmaceuticals, Inc. Announces Appointment of Peter Hillmen as Head of Hematology Engagement, Effective May 23, 2022

Apellis Pharmaceuticals, Inc. Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting

Insufficient new directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel recently sold €51k worth of stock

Forecast to breakeven in 2024

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Apellis Announces Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Apellis Announces U.S. Food and Drug Administration (Fda) Approval of Empaveli™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

ApApellis Pharmaceuticals, Inc. to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Apellis Pharmaceuticals, Inc. Provides Update on APL-9 for Severe COVID-19

New 90-day high: €46.60

Apellis Pharmaceuticals, Inc. Enters into A Commercial Supply Agreement with Bachem Americas, Inc

New 90-day high: €45.40

Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH

New 90-day high: €41.40

Sobi and Apellis Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan

Apellis Pharmaceuticals Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH

New 90-day high: €31.20

Apellis, Enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications Outside the US

Apellis Pharmaceuticals Announces 18-Month Data from Phase 1B Study of Pegcetacoplan in Patients with Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Observational Study Results That Found A Correlation Between Covid-19 Severity and Complement Overactivation

Apellis Pharmaceuticals, Inc. to Present Positive Results from the Phase 2 Discovery Study of Pegcetacoplan in C3 Glomerulopathy (C3g) At Asn Kidney Week

New 90-day high: €30.00

Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need